AC-0027838

AC-0027838 is an orally bioavailable, small molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK), currently under development by Acea Biosciences. It functions by forming a covalent bond with the cysteine residue (Cys481) in the active site of the BTK enzyme, thereby blocking its kinase activity. BTK is a critical component of the B-cell receptor (BCR) signaling pathway, which plays a vital role in the development, activation, and survival of B lymphocytes. By inhibiting BTK, AC-0027838 aims to treat B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune conditions like rheumatoid arthritis, where B-cell mediated signaling contributes to disease pathogenesis. The drug is designed to be highly selective for BTK to minimize off-target effects associated with first-generation inhibitors.